keyword
MENU ▼
Read by QxMD icon Read
search

lupus low disease activity state

keyword
https://read.qxmd.com/read/30679152/lupus-low-disease-activity-state-lldas-discriminates-responders-in-the-bliss-52-and-bliss-76-phase-iii-trials-of-belimumab-in-systemic-lupus-erythematosus
#1
Shereen Oon, Molla Huq, Vera Golder, Pei Xuan Ong, Eric F Morand, Mandana Nikpour
OBJECTIVE: We evaluated the discriminant capacity of the Lupus Low Disease Activity State (LLDAS) in post-hoc analysis of data from the BLISS-52 and BLISS-76 trials of belimumab in systemic lupus erythematosus (SLE). METHODS: LLDAS attainment, discrimination between belimumab and placebo arms, and the effects in subgroups with high disease activity at recruitment were evaluated at week 52 using appropriate descriptive statistics, χ2 test and logistic regression...
January 24, 2019: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/30678605/remission-and-low-disease-activity-state-ldas-are-protective-of-intermediate-and-long-term-outcomes-in-sle-patients-results-from-lumina-lxxviii-a-multiethnic-multicenter-us-cohort
#2
G S Alarcón, M F Ugarte-Gil, G Pons-Estel, L M Vilá, J D Reveille, G McGwin
OBJECTIVE: The objective of this report is to determine the impact of remission and low disease activity state (LDAS) on damage accrual and mortality in systemic lupus erythematosus (SLE) patients. PATIENTS AND METHODS: Visits from the Lupus in Minority populations: Nature vs. Nurture (LUMINA) cohort were categorized into remission (Systemic Lupus Activity Measure (SLAM) score = 0 and prednisone ≤ 5 mg/day and no immunosuppressants), LDAS ((not on remission), SLAM score ≤ 3, prednisone ≤ 7...
January 24, 2019: Lupus
https://read.qxmd.com/read/30637462/abnormal-amplitude-of-low-frequency-fluctuation-and-functional-connectivity-in-non-neuropsychiatric-systemic-lupus-erythematosus-a-resting-state-fmri-study
#3
Hong Yu, Xiang Qiu, Yu-Qing Zhang, Yan Deng, Mao-Yuan He, Yu-Ting Zhao, Zhao-Hua Zhai
PURPOSE: To explore the amplitude of low frequency fluctuation (ALFF) and functional connectivity (FC) disorders in non-neuropsychiatric systemic lupus erythematosus (non-NPSLE) patients by resting-state functional magnetic resonance imaging (rs-fMRI) and to study whether there are some clinical biomarkers that can be used to monitor the brain dysfunction. METHODS: Based on the rs-fMRI data of 36 non-NPSLE patients and 30 normal controls, we first obtained the regions with abnormal ALFF signals in non-NPSLE patients...
January 12, 2019: Neuroradiology
https://read.qxmd.com/read/30571926/clinical-sledai-2k-zero-may-be-a-pragmatic-outcome-measure-in-sle-studies
#4
Ioannis Parodis, Sharzad Emamikia, Alvaro Gomez, Iva Gunnarsson, Ronald F van Vollenhoven, Katerina Chatzidionysiou
OBJECTIVES: Development of therapies for systemic lupus erythematosus (SLE) has in part been limited by the lack of suitable outcome measures in clinical trials. In the present post-hoc analysis of two clinical trials of belimumab, we investigated two potential outcomes, the Lupus Low Disease Activity State (LLDAS) and clinical SLE disease activity index 2000 (cSLEDAI-2K) zero, in relation to SLE responder index 4 (SRI-4). METHODS: A total of 1684 SLE patients from the BLISS-52 (n=865) and BLISS-76 (n=819) trials were surveyed...
December 20, 2018: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/30551949/principal-component-analysis-reveals-disconnect-between-regulatory-cytokines-and-disease-activity-in-systemic-lupus-erythematosus
#5
Warren David Raymond, Gro Østli Eilertsen, Johannes Nossent
OBJECTIVE: Cytokine dysregulation contributes to inflammation and organ damage in Systemic Lupus Erythematosus (SLE). Principle Component Analysis (PCA) can determine which groups of cytokines have the most influence across disease activity states. MATERIAL AND METHOD: A cross-sectional study of age- and gender-matched SLE patients (n = 100) and controls (n = 31). SLE patients had a median Systemic Lupus Erythematosus Disease Activity Index - 2000 (SLEDAI-2K) score of 6 (IQR 2, 11)...
December 11, 2018: Cytokine
https://read.qxmd.com/read/30527426/update-on-the-epidemiology-risk-factors-and-disease-outcomes-of-systemic-lupus-erythematosus
#6
REVIEW
Irini Gergianaki, Alessandra Bortoluzzi, George Bertsias
Obtaining an updated view of the epidemiology, risk factors, and prognosis of systemic lupus erythematosus (SLE) is pivotal to our understanding of the disease burden. Recent community-based studies with comprehensive methodology provided more accurate disease occurrence estimates and suggested that SLE may be more frequent than previously thought. Gender, race, and socioeconomic status are important disease determinants, and there is increasing appreciation of the contribution of family history and environmental exposures in SLE susceptibility...
April 2018: Best Practice & Research. Clinical Rheumatology
https://read.qxmd.com/read/30415943/how-can-we-define-low-disease-activity-in-systemic-lupus-erythematosus
#7
Konstantinos Tselios, Dafna D Gladman, Murray B Urowitz
BACKGROUND: In recent years, low disease activity emerged as a state that is associated with improved long-term outcomes in systemic lupus erythematosus (SLE). Our aim was to review the current concepts for low disease activity in SLE in order to serve as the basis of a future consensus for standardization. METHODS: The PubMed database was searched for relevant articles from inception up to July 2018. Medical Subject Headings (MeSH terms) included "lupus" AND "low disease activity" OR "minimal disease activity"...
October 16, 2018: Seminars in Arthritis and Rheumatism
https://read.qxmd.com/read/30398013/development-of-the-asia-pacific-lupus-collaboration-cohort
#8
Rangi Kandane-Rathnayake, Vera Golder, Worawit Louthrenoo, Shue-Fen Luo, Yeong-Jian Jan Wu, Zhanguo Li, Yuan An, Aisha Lateef, Sargunan Sockalingam, Sandra V Navarra, Leonid Zamora, Laniyati Hamijoyo, Yasuhiro Katsumata, Masayoshi Harigai, Madelynn Chan, Sean O'Neill, Fiona Goldblatt, Yanjie Hao, Zhuoli Zhang, Jamal Al-Saleh, Munther Khamashta, Tsutomu Takeuchi, Yoshiya Tanaka, Sang-Cheol Bae, Chak Sing Lau, Alberta Hoi, Mandana Nikpour, Eric F Morand
AIM: The aim of this manuscript is to describe the development of the Asia Pacific Lupus Collaboration (APLC) cohort. METHOD: The APLC cohort is an ongoing, prospective longitudinal cohort. Adult patients who meet either the American College of Rheumatology (ACR) Modified Classification Criteria for systemic lupus erythematosus (SLE), or the Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria, and provide informed consent are recruited into the cohort...
November 5, 2018: International Journal of Rheumatic Diseases
https://read.qxmd.com/read/30397498/cytoplasmic-foxo1-identifies-a-novel-disease-activity-associated-b-cell-phenotype-in-sle
#9
Molly K Hritzo Ahye, Amit Golding
Systemic lupus erythematosus (SLE) is a manifestation of hyperactivated lymphocytes and results, in part, from the loss of normal tolerance checkpoints. FOXO1 is a transcription factor involved at critical early and late B cell development checkpoints; however, its role in regulating peripheral B cell tolerance is not fully understood. We have applied our published approach for using imaging flow cytometry to study native FOXO1 localisation in human lymphocytes to peripheral blood samples from healthy individuals versus patients with SLE...
2018: Lupus Science & Medicine
https://read.qxmd.com/read/30373882/response-to-lupus-low-disease-activity-state-lldas-attainment-discriminates-responders-in-a-systemic-lupus-erythematosus-trial-post-hoc-analysis-of-the-phase-iib-muse-trial-of-anifrolumab-by-eric-morand-et-al
#10
https://read.qxmd.com/read/30373881/response-to-response-to-lupus-low-disease-activity-state-lldas-attainment-discriminates-responders-in-a-systemic-lupus-erythematosus-trial-post-hocanalysis-of-the-phase-iib-muse-trial-of-anifrolumab-by-eric-morand-et-al-by-isenberg
#11
Eric F Morand, Teodora Trasieva, Anna Berglind, Gabor Illei, Raj Tummala
No abstract text is available yet for this article.
October 29, 2018: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/30120905/reply
#12
LETTER
Michelle Petri, Laurence S Magder
No abstract text is available yet for this article.
December 2018: Arthritis & Rheumatology
https://read.qxmd.com/read/30102390/progression-of-subclinical-atherosclerosis-in-systemic-lupus-erythematosus-versus-rheumatoid-arthritis-the-impact-of-low-disease-activity
#13
Evrydiki Kravvariti, George Konstantonis, Petros P Sfikakis, Maria G Tektonidou
Objectives: The progression of subclinical atherosclerosis in SLE and RA has not been comparatively assessed. We sought to investigate the impact of low disease activity and other disease-related factors on atherosclerosis progression in SLE vs RA. Methods: We performed a 3-year follow-up carotid and femoral artery ultrasound in 101 patients with SLE, 85 with RA and 85 controls after a baseline examination in 115 SLE and 1:1 age- and gender-matched RA patients and controls...
December 1, 2018: Rheumatology
https://read.qxmd.com/read/30009168/cd4-cd45ra-foxp3-low-regulatory-t-cells-as-potential-biomarkers-of-disease-activity-in-systemic-lupus-erythematosus-brazilian-patients
#14
Helena L Silva-Neta, Maria C A Brelaz-de-Castro, Mardonny B O Chagas, Henrique A Mariz, Rodrigo G de Arruda, Viviane F de Vasconcelos, Michelly C Pereira, Audrey Romano, Ivan R Pitta, Claudia D L Marques, Angela L B P Duarte, Moacyr J B M Rêgo, Maira G R Pitta
Heren, we analyzed Treg cells as potential biomarkers of disease activity in systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells from 30 SLE patients (15 active: SLEDAI > 6/15 SLE remission: SLEDAI< 6) and 15 healthy volunteers were purified. Treg immunophenotyping was performed using CD4, CD25, CD45, CD127, and FOXP3 markers. CD4+ FOXP3+ Treg activation state was investigated based on CD45RA and FOXP3 expression. To increase the accuracy of our findings, a multivariate linear regression was performed...
2018: BioMed Research International
https://read.qxmd.com/read/29806142/comparison-of-remission-and-lupus-low-disease-activity-state-in-damage-prevention-in-a-united-states-systemic-lupus-erythematosus-cohort
#15
Michelle Petri, Laurence S Magder
OBJECTIVE: One objective in the treatment of systemic lupus erythematosus (SLE) disease activity is to reduce long-term rates of organ damage. We undertook this study to analyze data from a large clinical SLE cohort to compare patients achieving different levels of disease activity with respect to rates of long-term damage. METHODS: We analyzed data from 1,356 SLE patients in the Hopkins Lupus Cohort, followed up quarterly, with 77,105 person-months observed from 1987 to 2016...
November 2018: Arthritis & Rheumatology
https://read.qxmd.com/read/29623845/is-treat-to-target-in-lupus-nephritis-realistic-in-clinical-practice
#16
Chi Chiu Mok
The Treat-to-Target (T2T) principle has been advocated in a number of inflammatory and non-inflammatory medical illnesses. Tight control of disease activity has been shown to improve the outcome of rheumatoid arthritis and psoriatic arthritis as compared to the conventional approach. However, whether T2T can be applied to patients with lupus nephritis is still under emerging discussion. Treatment of lupus nephritis should target at inducing and maintaining remission of the kidney inflammation so as to preserve renal function and improve survival in the longterm...
2019: Current Rheumatology Reviews
https://read.qxmd.com/read/29555348/low-disease-activity-irrespective-of-serologic-status-at-baseline-associated-with-reduction-of-corticosteroid-dose-and-number-of-flares-in-patients-with-systemic-lupus-erythematosus-treated-with-belimumab-a-real-life-observational-study
#17
Antonis Fanouriakis, Christina Adamichou, Sofia Koutsoviti, Stylianos Panopoulos, Chrysanthi Staveri, Anastasia Klagou, Christina Tsalapaki, Lamprini Pantazi, Styliani Konsta, Clio P Mavragani, Despoina Dimopoulou, Styliani Ntali, Georgios Katsikas, Kyriaki A Boki, Dimitrios Vassilopoulos, Pinelopi Konstantopoulou, Stamatis-Nick Liossis, Antonia Elezoglou, Maria Tektonidou, Prodromos Sidiropoulos, Abdulsamet Erden, Petros P Sfikakis, George Bertsias, Dimitrios T Boumpas
BACKGROUND: Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease activity states in real-life settings. METHODS: Multicentre prospective observational study of consecutive SLE patients receiving belimumab for at least 3 months, due to active disease refractory to at least one conventional immunosuppressant. Disease activity, including the recently defined lupus low disease activity state (LLDAS) and remission (clinical SLEDAI-2K = 0), accrual of organ damage, flares and side effects were documented...
February 23, 2018: Seminars in Arthritis and Rheumatism
https://read.qxmd.com/read/29531772/remission-and-low-disease-activity-in-systemic-lupus-erythematosus-an-achievable-goal-even-with-fewer-steroids-real-life-data-from-a-monocentric-cohort
#18
Chiara Tani, Roberta Vagelli, Chiara Stagnaro, Linda Carli, Marta Mosca
Objectives: To evaluate what proportion of patients fulfil the DORIS definition of remission, the definition of lupus low disease activity state (LLDAS) and LLDAS with a glucocorticoid (GC) dosage ≤5 (LLDAS5) in a longitudinal monocentric cohort of patients with SLE; to identify predictors of sustained remission and LLDAS attainment; to evaluate the effect of sustained remission and LLDAS on damage accrual over a period of 5 years and compare the two conditions in terms of clinical outcomes...
2018: Lupus Science & Medicine
https://read.qxmd.com/read/29420200/lupus-low-disease-activity-state-lldas-attainment-discriminates-responders-in-a-systemic-lupus-erythematosus-trial-post-hoc-analysis-of-the-phase-iib-muse-trial-of-anifrolumab
#19
Eric F Morand, Teodora Trasieva, Anna Berglind, Gabor G Illei, Raj Tummala
OBJECTIVES: In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State (LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb randomised controlled trial (RCT) (MUSE [NCT01438489]) and then utilize LLDAS to discriminate between anifrolumab and placebo. METHODS: Patients received intravenous placebo (n=102) or anifrolumab (300 mg, n=99; 1,000 mg, n=104) Q4W plus standard of care for 48 weeks. LLDAS attainment (SLE Disease Activity Index 2000 ≤4 without major organ activity, no new disease activity, Physician's Global Assessment ≤1, prednisolone ≤7...
May 2018: Annals of the Rheumatic Diseases
https://read.qxmd.com/read/29224676/treat-to-target-remission-and-low-disease-activity-in-sle
#20
REVIEW
Eric F Morand, Marta Mosca
Despite improvements in survival, outcomes of contemporary treatment of systemic lupus erythematosus (SLE) are unacceptable. Unlike in many diseases, treat-to-target (T2T) approaches have not been adopted in SLE, owing to a lack of validated targets to treat towards. Therefore, it is a key goal to validate target state definitions such as low disease activity and remission, and test their implementation in clinical practice and clinical trials. In this article, we review recent advances in T2T approaches in SLE, and emerging evidence-based consensus on definitions of remission and low disease activity that are needed to underpin such approaches...
June 2017: Best Practice & Research. Clinical Rheumatology
keyword
keyword
169196
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"